Price movement over the last 24 hours
Align Technology, Inc. vs UnitedHealth Group Inc — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while UnitedHealth Group Inc trades at $425.17 (market cap $385.62B). The key difference: UnitedHealth Group Inc is far larger — about 30× Align Technology, Inc.'s market cap, and UnitedHealth Group Inc pays a 2.19% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | UNH | |
|---|---|---|
Market Cap | $12.86B | $385.62B |
Sector | Health | Health |
52-Week High | $207.19 | $431.68 |
52-Week Low | $124.88 | $237.77 |
Enterprise Value | $11.92B | $432.30B |
Dividend Yield | — | 2.19% |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
UnitedHealth Group (UNH) trades at $424.62, down 1.64% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $7.23 versus $6.58 expected. Revenue grew to $447.57 billion in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
UNH presents a favorable risk-reward profile with 82.7% analyst buy ratings and a consensus price target of $423.18, near the current price. Key opportunities include demographic tailwinds from an aging population and tech-driven efficiency gains. Risks involve regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. The stock's valuation at a P/E of 31.97 requires sustained earnings growth to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →